The Wall Street Journal reports that Health Secretary Robert F. Kennedy Jr. plans to release a study linking Tylenol use during pregnancy and folate deficiency to autism, with recommendations for folinic acid as a potential treatment. Shares of Kenvue, the company that produces Tylenol, dropped 10% following the report. The findings, expected from the Department of Health and Human Services, suggest low folate levels and Tylenol use during pregnancy may contribute to autism, which affects roughly one in 31 eight-year-olds in the U.S. The report also highlights folinic acid as a possible intervention for some individuals with autism.
The American College of Obstetricians and Gynecologists states Tylenol is generally safe during pregnancy but advises consulting healthcare providers before use. Critics have raised concerns about the potential link between vaccines and autism, though no evidence has been presented to support this claim. Some argue that reduced vaccination rates in Marin County, California, around 2000 coincided with a decline in autism diagnoses, but studies have not confirmed a causal relationship.
The discussion has sparked broader debates about vaccine safety, with some questioning the role of pharmaceutical companies and public health policies. Bill Ackman, a financier, recently spoke out against mandatory vaccination schedules for infants, calling for independent reviews of vaccine protocols. Others have raised alarms about ingredients in vaccines, including aluminum and polysorbate 80, citing potential health risks.
The article also touches on controversies surrounding the COVID-19 vaccines, with claims of toxic effects and concerns over long-term health impacts. While some experts dismiss these allegations as unfounded, others advocate for greater transparency in vaccine development and administration. The debate continues amid growing public scrutiny of medical authority and pharmaceutical practices.
